Your browser is no longer supported. Please, upgrade your browser.
AXSM [NASD]
Axsome Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.77 Insider Own21.47% Shs Outstand37.35M Perf Week-5.79%
Market Cap2.12B Forward P/E- EPS next Y-1.92 Insider Trans0.00% Shs Float29.50M Perf Month5.31%
Income-102.90M PEG- EPS next Q-0.87 Inst Own65.30% Short Float9.81% Perf Quarter-24.31%
Sales- P/S- EPS this Y-37.70% Inst Trans0.06% Short Ratio8.11 Perf Half Y-23.78%
Book/sh3.05 P/B18.68 EPS next Y50.80% ROA-52.90% Target Price- Perf Year-37.97%
Cash/sh4.95 P/C11.51 EPS next 5Y- ROE-73.60% 52W Range50.05 - 94.10 Perf YTD-30.08%
Dividend- P/FCF- EPS past 5Y-22.00% ROI- 52W High-39.47% Beta2.54
Dividend %- Quick Ratio7.90 Sales past 5Y- Gross Margin- 52W Low13.81% ATR3.03
Employees60 Current Ratio7.90 Sales Q/Q- Oper. Margin- RSI (14)47.90 Volatility4.39% 5.51%
OptionableYes Debt/Eq0.42 EPS Q/Q-9.40% Profit Margin- Rel Volume0.87 Prev Close56.36
ShortableYes LT Debt/Eq0.42 EarningsMay 10 BMO Payout- Avg Volume356.92K Price56.96
Recom1.70 SMA202.23% SMA50-4.85% SMA200-20.39% Volume309,527 Change1.06%
Jan-08-21Initiated Jefferies Buy $129
Dec-16-20Initiated Mizuho Buy $120
Sep-29-20Initiated BofA Securities Underperform $66
Sep-10-20Initiated Morgan Stanley Overweight $102
Apr-28-20Reiterated H.C. Wainwright Buy $200 → $210
Apr-14-20Initiated Cowen Outperform $95
Dec-30-19Reiterated H.C. Wainwright Buy $170 → $200
Dec-17-19Reiterated H.C. Wainwright Buy $30 → $170
Dec-16-19Reiterated Guggenheim Buy $65 → $158
Oct-16-19Initiated Guggenheim Buy $48
Sep-18-19Initiated William Blair Outperform
May-28-19Initiated SunTrust Buy
May-23-19Reiterated H.C. Wainwright Buy $23 → $30
Apr-08-19Initiated SVB Leerink Outperform $25
Mar-15-19Reiterated H.C. Wainwright Buy $15 → $18
Oct-03-16Resumed Brean Capital Buy
Dec-15-15Initiated Cantor Fitzgerald Buy
Dec-14-15Initiated Ladenburg Thalmann Buy
May-07-21 08:44AM  
07:00AM  
Apr-30-21 06:25AM  
Apr-28-21 06:20AM  
Apr-27-21 07:00AM  
Apr-26-21 12:16PM  
12:00PM  
07:54AM  
06:00AM  
Apr-24-21 11:00AM  
Apr-22-21 12:05PM  
09:15AM  
Mar-31-21 11:30AM  
Mar-30-21 02:05AM  
Mar-11-21 10:06AM  
Mar-02-21 09:40AM  
Mar-01-21 06:30PM  
07:00AM  
06:30AM  
Feb-19-21 07:00AM  
Feb-16-21 07:00AM  
Feb-10-21 06:00AM  
Jan-27-21 07:05AM  
Jan-07-21 08:48AM  
Jan-04-21 09:30AM  
Dec-31-20 06:15AM  
06:00AM  
Dec-30-20 12:25AM  
Dec-17-20 05:25PM  
Dec-08-20 06:00AM  
Dec-05-20 11:31AM  
Dec-02-20 06:00AM  
Dec-01-20 06:00AM  
Nov-06-20 11:31PM  
11:30AM  
Nov-05-20 07:00AM  
06:15AM  
Nov-04-20 07:03AM  
07:03AM  
Nov-03-20 07:00AM  
Oct-28-20 07:00AM  
Oct-01-20 11:14AM  
Sep-29-20 12:00PM  
07:00AM  
Sep-24-20 06:00AM  
Sep-22-20 12:19PM  
Sep-21-20 07:00AM  
Sep-17-20 07:00AM  
Sep-15-20 12:46AM  
Sep-14-20 06:00AM  
Sep-10-20 07:00AM  
Sep-09-20 11:30AM  
Sep-08-20 07:00AM  
Sep-03-20 07:00AM  
Aug-31-20 07:00AM  
Aug-28-20 07:00AM  
Aug-20-20 07:00AM  
Aug-11-20 01:05PM  
Aug-10-20 04:44PM  
07:05AM  
07:00AM  
Aug-05-20 07:00AM  
Jul-30-20 07:00AM  
Jul-25-20 07:10AM  
Jul-16-20 12:21PM  
Jul-15-20 01:15PM  
12:05PM  
Jul-14-20 12:16PM  
Jul-13-20 07:00AM  
Jul-08-20 02:41PM  
Jul-07-20 11:14AM  
Jul-03-20 03:19PM  
Jun-29-20 12:49PM  
Jun-26-20 07:00AM  
Jun-15-20 12:24PM  
Jun-07-20 11:30AM  
Jun-04-20 06:27PM  
07:00AM  
May-29-20 01:38PM  
07:00AM  
May-26-20 12:57PM  
07:00AM  
May-23-20 07:36AM  
May-19-20 06:04AM  
May-11-20 11:56AM  
May-09-20 02:00PM  
08:10AM  
06:47AM  
May-08-20 07:00AM  
May-03-20 03:39PM  
Apr-30-20 08:00AM  
07:00AM  
Apr-28-20 11:16AM  
Apr-27-20 06:00AM  
Apr-07-20 12:37PM  
Apr-06-20 06:00AM  
Apr-01-20 01:23PM  
Mar-31-20 05:05PM  
04:52PM  
Mar-30-20 06:00AM  
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coleman MarkDirectorJun 29Buy78.5065051,025403,698Jun 30 08:20 AM
Pizzie NickChief Financial OfficerJun 29Buy76.6477759,54941,217Jun 30 08:19 AM